Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

713 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bladder cancer: molecular determinants of personalized therapy.
Lopez-Beltran A, Santoni M, Massari F, Ciccarese C, Tortora G, Cheng L, Moch H, Scarpelli M, Reymundo C, Montironi R. Lopez-Beltran A, et al. Among authors: moch h. Curr Drug Targets. 2015;16(2):115-24. doi: 10.2174/1389450116666150204115756. Curr Drug Targets. 2015. PMID: 25654736 Review.
Current pathology keys of renal cell carcinoma.
Algaba F, Akaza H, López-Beltrán A, Martignoni G, Moch H, Montironi R, Reuter V. Algaba F, et al. Among authors: moch h. Eur Urol. 2011 Oct;60(4):634-43. doi: 10.1016/j.eururo.2011.06.047. Epub 2011 Jul 3. Eur Urol. 2011. PMID: 21741159 Review.
Renal tumors: diagnostic and prognostic biomarkers.
Tan PH, Cheng L, Rioux-Leclercq N, Merino MJ, Netto G, Reuter VE, Shen SS, Grignon DJ, Montironi R, Egevad L, Srigley JR, Delahunt B, Moch H; ISUP Renal Tumor Panel. Tan PH, et al. Among authors: moch h. Am J Surg Pathol. 2013 Oct;37(10):1518-31. doi: 10.1097/PAS.0b013e318299f12e. Am J Surg Pathol. 2013. PMID: 24025522 Free PMC article.
Biomarkers in renal cancer.
Moch H, Srigley J, Delahunt B, Montironi R, Egevad L, Tan PH. Moch H, et al. Virchows Arch. 2014 Mar;464(3):359-65. doi: 10.1007/s00428-014-1546-1. Epub 2014 Feb 1. Virchows Arch. 2014. PMID: 24487793 Review.
Molecular foundations for personalized therapy in prostate cancer.
Fisher KW, Montironi R, Lopez Beltran A, Moch H, Wang L, Scarpelli M, Williamson SR, Koch MO, Cheng L. Fisher KW, et al. Among authors: moch h. Curr Drug Targets. 2015;16(2):103-14. doi: 10.2174/1389450115666141229154500. Curr Drug Targets. 2015. PMID: 25547910 Review.
Oncotargets in different renal cancer subtypes.
Moch H, Montironi R, Lopez-Beltran A, Cheng L, Mischo A. Moch H, et al. Curr Drug Targets. 2015;16(2):125-35. doi: 10.2174/1389450116666150126110632. Curr Drug Targets. 2015. PMID: 25619751 Review.
An Overview of Emerging Immunotargets of Genitourinary Tumors.
Montironi R, Santoni M, Cheng L, Lopez-Beltran A, Massari F, Matrana MR, Moch H, Scarpelli M. Montironi R, et al. Among authors: moch h. Curr Drug Targets. 2016;17(7):750-6. doi: 10.2174/1389450117666151209144649. Curr Drug Targets. 2016. PMID: 26648079 Review.
Emerging Immunotargets and Immunotherapies in Prostate Cancer.
Montironi R, Santoni M, Sotte V, Cheng L, Lopez-Beltran A, Massari F, Matrana MR, Moch H, Berardi R, Scarpelli M. Montironi R, et al. Among authors: moch h. Curr Drug Targets. 2016;17(7):777-82. doi: 10.2174/1389450117666160217123304. Curr Drug Targets. 2016. PMID: 26898309 Review.
713 results